In the last several decades, advancements in chemotherapy have improved the overall survival of cancer patients. These agents, however, are associated with adverse effects, including various kidney lesions. This review summarizes the nephrotoxic potential of chemotherapy agents, old and new, as well as the different factors that contribute to kidney injury. Provided for each class of chemotherapy agent is the associated kidney lesion and a brief discussion of clinical manifestation, mechanism of action, and possible treatment when available. Understanding the nephrotoxic potential these agents have on the kidneys is imperative for both the oncologist and the nephrologist to properly care for cancer patients and ensure their best outcomes.

Dr. Anthony Nicolaysen was born in Salem, Oregon in 1990. Attended New York University where he double-majored in biochemistry and anthropology, graduating cum laude in 2012. He attended medical school at Oregon Health & Science University, graduating in 2018. He currently an internal medicine resident at Mount Sinai Beth Israel Hospital in New York City with plans of pursuing a fellowship in nephrology. He enjoys traveling, cooking, music, films, golfing, and skiing.